1. 首頁 > 健康養生 > >

一文看遍！這些ASH最新抗癌進展值得關注( 四 )

健康知識養生常識


CD20靶向CARγδ-T細胞療法治療LBCL患者結果出色
AdicetBio公布其同種異體、“現貨型”CD20靶向CARγδ-T細胞療法ADI-001 ， 用于治療R/RB細胞非霍奇金淋巴瘤（NHL）的最新劑量遞增臨床1期試驗數據 。 分析顯示 ， 在所有劑量當中 ， ADI-001達成75%的ORR以及69%的CR ， 并展現良好的安全性 。 值得一提的是 ， 在之前曾接受過靶向CD19CAR-T療法的5位LBCL患者中 ， 達成了100%（5/5）的ORR與CR 。 此外 ， 在接受劑量水平3或以上的LBCL患者中 ， 亦達成了86%的CR 。
BMS靶向GPRC5D自體CAR-T療法展現早期療效成果
BMS公布其靶向GPRC5D自體CAR-T療法BMS-986393于治療RRMM患者的臨床1期最新數據 。 在進行中期分析時 ， BMS-986393展現良好的安全性 ， 所出現的CRS多數低級別、暫時性 。 在中位追蹤期5.82個月的患者分析中 ， 患者達到89.5%的ORR（17/19）以及47.4%（9/19）的CR 。
希望這些亮眼的臨床數據 ， 能夠盡早轉化為臨床應用治療 ， 為更多血液腫瘤的病患改善生活品質與治療結果！
??
?
?
參考資料：
[1]Real-WorldStudyShowsPatientsTreatedwithIMBRUVICA?(ibrutinib)WereLessLikelytoInitiateaNext-LineTreatmentthanPatientsonAcalabrutinibinFirst-lineChronicLymphocyticLeukemia.RetrievedDecember12,2022fromhttps://www.jnj.com/real-world-study-shows-patients-treated-with-imbruvica-ibrutinib-were-less-likely-to-initiate-a-next-line-treatment-than-patients-on-acalabrutinib-in-first-line-chronic-lymphocytic-leukemia
[2]COGENTBIOSCIENCESANNOUNCESPOSITIVEUPDATEDCLINICALDATAFROMONGOINGPHASE2APEXTRIALEVALUATINGBEZUCLASTINIBINPATIENTSWITHADVANCEDSYSTEMICMASTOCYTOSIS(ADVSM).RetrievedDecember12,2022fromhttps://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-positive-updated-clinical-data
[3]AbbViePresentsDataatthe64thAmericanSocietyofHematology(ASH)AnnualMeetingforInvestigationalNavitoclaxinCombinationWithRuxolitinibforJAKInhibitor-Na?veMyelofibrosisPatients.RetrievedDecember12,2022fromhttps://news.abbvie.com/news/press-releases/abbvie-presents-data-at-64th-american-society-hematology-ash-annual-meeting-for-investigational-navitoclax-in-combination-with-ruxolitinib-for-jak-inhibitor-nave-myelofibrosis-patients.htm
[4]LoxoOncologyatLillyAnnouncesUpdatedDatafromthePhase1/2BRUINClinicalTrialforPirtobrutinibattheAmericanSocietyofHematologyAnnualMeeting.RetrievedDecember12,2022fromhttps://investor.lilly.com/news-releases/news-release-details/loxo-oncology-lilly-announces-updated-data-phase-12-bruin-1
[5]BristolMyersSquibbAnnouncesFirstDisclosuresandNewDataatASH2022,DemonstratingCommitmenttoRaisingStandardsinTreatmentThroughBroadMultipleMyelomaPortfolio.RetrievedDecember12,2022fromhttps://news.bms.com/news/corporate-financial/2022/Bristol-Myers-Squibb-Announces-First-Disclosures-and-New-Data-at-ASH-2022-Demonstrating-Commitment-to-Raising-Standards-in-Treatment-Through-Broad-Multiple-Myeloma-Portfolio/default.aspx
[6]KymeraTherapeuticsPresentsPreclinicalDataDemonstratingActivityofKT-253,aSelectiveHeterobifunctionalMDM2Degrader,inAcuteMyeloidLeukemiaattheAmericanSocietyofHematologyAnnualMeetingRetrievedDecember12,2022fromhttps://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-presents-preclinical-data-demonstrating
[7]GenentechPresentsNewandUpdatedDataforPolivyinPreviouslyUntreatedDiffuseLargeB-CellLymphomaatASH2022.RetrievedDecember12,2022fromhttps://www.gene.com/media/press-releases/14976/2022-12-11/genentech-presents-new-and-updated-data-
[8]PfizerPresentsUpdatedFavorableElranatamabDatafromPivotalPhase2MagnetisMM-3Trial.RetrievedDecember12,2022fromhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-presents-updated-favorable-elranatamab-data-pivotal
[9]PIVOTALODRONEXTAMAB(CD20XCD3)PHASE2DATAINPATIENTSWITHRELAPSED/REFRACTORYDIFFUSELARGEB-CELLLYMPHOMADEBUTATASH.RetrievedDecember12,2022fromhttps://investor.regeneron.com/news-releases/news-release-details/pivotal-odronextamab-cd20xcd3-phase-2-data-patients